Compare MMU & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMU | EOLS |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 454.4M |
| IPO Year | N/A | 2018 |
| Metric | MMU | EOLS |
|---|---|---|
| Price | $10.09 | $6.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 128.8K | ★ 718.6K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $9.79 | $3.86 |
| 52 Week High | $10.71 | $9.42 |
| Indicator | MMU | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 46.33 |
| Support Level | $9.91 | $5.45 |
| Resistance Level | $10.47 | $6.25 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 9.41 | 38.83 |
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.